Kush Bottles Inc (OTCMKTS:KSHB) was featured in an investor oriented webinar, held by New Cannabis Ventures. This webinar was hosted on July 19, 2017. Nicholas Kovacevich, the CEO and Co-Founder, discussed the firm’s recent performance and resolved queries of attendees. New Cannabis, a major cannabis industry investment journal, has been key in promoting transparency and higher standards within the sector.
New Cannabis wrote that Kush recently closed a transformational acquisition deal and is a major revenue generator in the cannabis division. One of the themes they have been highlighting in 2017 is revenue, something that was mainly not seen from the publicly-traded equities many years ago, but is getting much more visibility in 2017. Gone is the period when public firm investors invested in pre-revenue firms, and this change is applicable to both ancillary and direct cannabis firms. One of the major public-firm revenue generators is Kush.
Prior to webinar, Kovacevich reported that he had been looking forward to the webinar and getting an opportunity to resolve queries, especially from investors. They are proud of their accomplishments and always enjoy talking about their development, as well as discuss the prospects that lies ahead. Registrants to the webinar will get a free recording following the meeting concludes.
Kush is marked as a dynamic sales platform that delivers unique services and products for both consumers and businesses in the cannabis market. Established in 2010 as a supplies and packaging firm for dispensaries and cultivators, Kush Bottles has offered over 100 million units and now repeatedly services over 4,000 legally managed adult-use and medical dispensaries, producers and growers across South America, Europe and North America.
The firm has facilities in the three leading U.S. cannabis industries and a local sales presence in all major United States cannabis market. Kush Bottles intends to be the gold standard for compliant and responsible services and offerings in the cannabis industry.
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…